CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lymphomas.
  
  LEARNING OBJECTIVES

  • Understand published research data informing the selection, sequencing and combining of available therapeutic agents in the nonresearch care of patients with previously untreated or relapsed/refractory (R/R) follicular lymphoma (FL).
  • Recognize the mechanisms of action, efficacy and safety of approved and investigational agents for the treatment of diffuse large B-cell lymphoma (DLBCL) to determine the current and potential utility of those therapies in clinical practice.
  • Consider patient age, performance status and other clinical and biologic factors in the selection of up-front and subsequent therapy for mantle cell lymphoma (MCL).
  • Incorporate available and emerging therapeutic strategies into the best-practice management of newly diagnosed and R/R Hodgkin lymphoma (HL).
  • Assess available clinical trial findings informing the utilization of CD19-directed chimeric antigen receptor T-cell therapy for R/R DLBCL, MCL and FL, and counsel appropriately selected patients regarding the potential benefits of this strategy.
  • Implement a plan of care to recognize and manage side effects and toxicities associated with existing and recently approved systemic therapies for FL, DLBCL, MCL and HL to support quality of life and continuation of treatment.
  • Recall new data with agents and strategies currently under investigation for HL and various forms of non-Hodgkin lymphoma, and discuss ongoing trial opportunities with eligible patients.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Jonathan W Friedberg, MD, MMSc
  Samuel E Durand Professor of Medicine
  Director, James P Wilmot Cancer Institute
  University of Rochester
  Rochester, New York
  
  No relevant conflicts of interest to disclose.
  
  Brad S Kahl, MD
  Professor of Medicine
  Washington University School of Medicine
  Director, Lymphoma Program
  Siteman Cancer Center
  St Louis, Missouri
  
  No relevant conflicts of interest to disclose.
  
  David G Maloney, MD, PhD
  Professor, Clinical Research Division
  Medical Director
  Cellular Immunotherapy and the Bezos Family
  Immunotherapy Clinic
  Leonard and Norma Klorfine Endowed Chair
  for Clinical Research
  Fred Hutchinson Cancer Center
  Professor of Medicine, Division of Oncology
  University of Washington
  Seattle, Washington
  
  Advisory Committee: Chimeric Therapeutics, Genentech, a member of the Roche Group; Consulting Agreements: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Celgene Corporation, Gilead Sciences Inc, Incyte Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Lilly, Mustang Bio, Novartis, Umoja Biopharma; Contracted Research: Celgene Corporation, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech.
  
  Loretta J Nastoupil, MD
  Associate Professor
  Section Chief, Indolent Lymphoma
  Section Chief, New Drug Development
  Department of Lymphoma/Myeloma
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Advisory Committee: Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Novartis, Takeda Pharmaceuticals USA Inc; Contracted Research: Bristol-Myers Squibb Company, Caribou Biosciences Inc, Epizyme Inc, Genentech, a member of the Roche Group, Genmab, IGM Biosciences Inc, Janssen Biotech Inc, Kite, A Gilead Company, Novartis, Takeda Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Denovo Biopharma, Genentech, a member of the Roche Group, MEI Pharma Inc, Takeda Pharmaceuticals USA Inc.
  
  Sonali M Smith, MD
  Elwood V Jensen Professor of Medicine
  Chief, Section of Hematology/Oncology
  Co-Leader, Cancer Service Line
  Co-Director, Lymphoma Program
  The University of Chicago
  Chicago, Illinois
  
  Consulting Agreements: Bristol-Myers Squibb Company, Gilead Sciences Inc, MorphoSys; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Bristol-Myers Squibb Company, Celgene Corporation, Curis Inc, Epizyme Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Karyopharm Therapeutics, Pharmacyclics LLC, an AbbVie Company, Portola Pharmaceuticals Inc, TG Therapeutics Inc; Nonrelevant Financial Relationship: Spouse is employed at Caris Life Sciences.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from ADC Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Genentech, a member of the Roche Group, Kite, A Gilead Company, MEI Pharma Inc, Novartis, and Seagen Inc.
  
  Release date: January 2023
  Expiration date: January 2024